Navigation Links
Sapheneia / Scannerside Announces FDA 510(K) Clearance for New 2nd Gen XR 29 Dose Check
Date:9/5/2017

KEYSTONE, Colo., Sept. 5, 2017 /PRNewswire/ -- Sapheneia and Scannerside received FDA 510(k) clearance to market their XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor neutral CT product that makes it affordable to update existing CT scanners and allows compliance with current MITA standards.

The Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed to provide CT operators, prior to a scan, notifications and alerts of potential radiation doses over a predefined threshold. Scannerside Dose Check is intended to be installed and used with CT scanners not equipped with these functionalities, independent of age, make, and model. This newly introduced DoseCheck system encompasses a proprietary hardware and software solution with additional features that NO other third-party solution can offer. "We believe the latest comprehensive solution will be the backbone to solving XR25/29 and beyond upgrades for legacy Scanners," says Paul Stashick, CEO Sapheneia Inc.

Sapheneia has a long successful history of low-dose applications for CT users, since being the first third-party software company that received FDA clearance for the Clarity low-dose software (2007).  Sapheneia Inc. and Scannerside became business partners, combining Low Dose CT (LDCT), Dose Monitoring, and XR-29 scanner upgrades, thereby becoming the first Single Source CT Dose solution provider.

Now that Scannerside DoseCheck has been FDA 510(k) approved the partnership between Sapheneia-Scannerside can help a facility reach all the requirements for XR-29 compliance. 

ABOUT SAPHENEIA INC.  
Sapheneia Inc. is a U.S. technologies company specializing in diagnostic and analytical image processing solutions. For more than a decade, Sapheneia software has been in routine, clinical use at major hospitals and imaging centers worldwide, supporting CT scanner systems from all manufacturers, including GE, Philips, Siemens, and Toshiba. The solutions provided by Sapheneia range from its Comprehensive Dose Strategy (CDS) for X-Ray, NM and CT to supplying some of the world's largest equipment manufacturers with software for ultrasound and other modalities. www.Sapheneia.com

ABOUT SCANNERSIDE
Scannerside hardware/software solutions are created by academic radiologist. With the objective of creating practical solutions by doctors for doctors. Scannerside continues its forefront market position by monitoring compliance laws and building applications that satisfy the current legislation with rapid product deployment. www.Scannerside.com

Contact:
Paul Stashick
174838@email4pr.com 
888-342-5619

View original content:http://www.prnewswire.com/news-releases/sapheneia--scannerside-announces-fda-510k-clearance-for-new-2nd-gen-xr-29-dose-check-300513800.html


'/>"/>
SOURCE Sapheneia Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Oramed Announces Successful Meeting with FDA for Oral Insulin
2. Explorers Like Us Announces "An American Sojourn" -- The First Interactive Production to Capture Americas Spectacular 3D Aural Experience
3. West Announces Fall Investor Conference Schedule
4. BioBridges Announces Corporate Sponsorship of Battle of the Biotech Bands
5. AOTI Inc. Announces New York City Office Grand Opening
6. BrainStorm Announces Second Quarter 2017 Financial Results
7. Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2017
8. Diplomat Announces A New President
9. Diplomat Announces 2nd Quarter Financial Results
10. Endo Announces Agreements to Resolve Virtually All Known U.S. Mesh Product Liability Claims
11. West Announces Second-Quarter 2017 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
Breaking Medicine Technology:
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):